Heart Failure With Mildly Reduced Ejection Fraction Registry

NCT05603390 | Unknown

• 1 other identifier: 2022-818
• Study Type: observational
• Target: 2,200
• Locations: 1 country
• Sites: 1

Brief Summary

Heart failure (HF) affects about 1% of patients younger than 55 years, whereas the prevalence of HF increases \> 10% in patients with at least 70 years of age. Despite HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the clinical significance of HF with mildly reduced ejection fraction (HFmrEF) has gained more importance within the past years. Those patients are characterized by a left ventricular ejection fraction (LVEF) of 41-49%. However, within the current European guidelines, limited treatment recommendations in this subgroup of HF are yet available as a consequence of the limited number of studies in this field. The "Heart Failure With Mildly Reduced Ejection Fraction Registry" aims to characterize patients with HFmrEF and investigated the prognostic impact of interventional and pharmacological therapies in this subgroup of HF patients.

Conditions

Heart Failure

Outcome Measures

Primary Outcomes (1)

• All-cause mortality

  All-cause mortality

  2 years.

Secondary Outcomes (3)

• Change of LVEF

  2 years.

• Change of NT-pro BNP

  2 years.

• Heart-failure related hospitalization

  2 years.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The present study consecutively includes patients with heart failure with mildly reduced ejection fraction (HFmrEF) from 2015 to 2022.

You may qualify if:

• Patients with HFmrEF (i.e., LVEF 41-49%)
• Patients with at least 18 years of age

You may not qualify if:

• Patients younger than 18 years of age

Sponsors & Collaborators

• Universitätsmedizin Mannheim: lead

Study Sites (1)

University Medical Centre Mannheim

Mannheim, 68167, Germany

RECRUITING

Related Publications (2)

• Schmitt A, Akin I, Reinhardt M, Abel N, Lau F, Dudda J, Abumayyaleh M, Weidner K, Bertsch T, Duerschmied D, Behnes M, Schupp T. Albumin, urea-to-albumin ratio, or the albumin-to-creatinine ratio to predict outcomes in heart failure with mildly reduced ejection fraction. Eur J Clin Invest. 2026 Jan;56(1):e70165. doi: 10.1111/eci.70165. Epub 2025 Dec 26.

  PMID: 41452958 DERIVED

• Reinhardt M, Behnes M, Weidner K, Abumayyaleh M, Lau F, Schmitt A, Abel N, Duerschmied D, Weiss C, Akin M, Akin I, Schupp T. Prognostic Implications of Sex in Patients With Heart Failure With Mildly Reduced Ejection Fraction: Results From a Large-Scaled Registry. J Am Heart Assoc. 2025 Jan 21;14(2):e033173. doi: 10.1161/JAHA.123.033173. Epub 2025 Jan 16.

  PMID: 39817535 DERIVED

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Officials

• Michael Behnes, MD

  First Department of Medicine, University Medical Centre Mannheim, Germany.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Behnes, MD

CONTACT

+496213836239; michael.behnes@umm.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr. med. Michael Behnes

Study Record Dates

• First Submitted: October 10, 2022
• First Posted: November 2, 2022
• Study Start: January 1, 2015
• Primary Completion: January 1, 2022
• Study Completion: January 1, 2023
• Last Updated: November 2, 2022

Record last verified: 2022-10

Locations

DE (1)